Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Other Operating Expenses (2016 - 2025)

Immucell's Other Operating Expenses history spans 16 years, with the latest figure at $486643.0 for Q4 2025.

  • For Q4 2025, Other Operating Expenses changed N/A year-over-year to $486643.0; the TTM value through Dec 2025 reached $426587.0, down 45.75%, while the annual FY2025 figure was $426587.0, N/A changed from the prior year.
  • Other Operating Expenses reached $486643.0 in Q4 2025 per ICCC's latest filing, up from -$62319.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $992556.0 in Q4 2022 to a low of -$396629.0 in Q2 2022.
  • Average Other Operating Expenses over 5 years is $377616.1, with a median of $486643.0 recorded in 2025.
  • The largest YoY upside for Other Operating Expenses was 9816.4% in 2024 against a maximum downside of 19005.19% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $889929.0 in 2021, then rose by 11.53% to $992556.0 in 2022, then fell by 17.64% to $817486.0 in 2023, then tumbled by 101.78% to -$14557.0 in 2024, then soared by 3443.02% to $486643.0 in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Other Operating Expenses are $486643.0 (Q4 2025), -$62319.0 (Q3 2025), and $7128.0 (Q2 2025).